CorMedix Shares Climb With Higher 1Q Profit, Sales

Dow Jones

05/15

By Christopher Kuo

CorMedix shares rose after the company reported higher first-quarter profit and revenue.

Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.

The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.

Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.

"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand," said Chief Executive Joseph Todisco. "In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity."

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 14, 2026 14:44 ET (18:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2635747065"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635747065\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635747065?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 02:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635747065","market":"nz","top_or_hot":-1,"title":"CorMedix Shares Climb With Higher 1Q Profit, Sales","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n</p>\n<p>\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n</p>\n<p>\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n</p>\n<p>\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 14:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Climb With Higher 1Q Profit, Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Climb With Higher 1Q Profit, Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-15 02:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n</p>\n<p>\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n</p>\n<p>\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n</p>\n<p>\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2026 14:44 ET (18:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2635747065","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635747065","pubTimestamp":1778784240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"CorMedix shares rose after the company reported higher first-quarter profit and revenue.Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date.The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share.Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter.\"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stag","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc.","BK4007":"制药"},"translate_title":"CorMedix股价上涨，第一季度利润和销售额增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  CorMedix shares rose after the company reported higher first-quarter profit and revenue. \n\n\n  Shares of the biopharmaceutical company rose 8.5% on Thursday to $8.14. The company's shares are still down more than 30% year to date. \n\n\n  The company on Thursday posted a first-quarter profit of $38.6 million, or 43 cents a share, compared with $20.6 million, or 30 cents a share, a year earlier. Analysts polled by FactSet expected 34 cents a share. \n\n\n  Revenue rose to $127.4 million from $39.1 million in the year-ago quarter. Analysts expected $105 million. The company's sales increased largely due to the onboarding of a large dialysis organization in mid 2025, the company said. Sales of DefenCath, the company's catheter lock solution, contributed $97.5 million in revenue in the quarter. \n\n\n  \"DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,\" said Chief Executive Joseph Todisco. \"In addition, we are advancing a pipeline of late-stage opportunities, including Rezzayo for prophylaxis, which we expect will meaningfully expand our long-term revenue opportunity.\" \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 14:44 ET (18:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}